Results 171 to 180 of about 39,119 (216)

Moxifloxacin and Sitafloxacin Treatment Failure in Mycoplasma genitalium Infection: Association with parC Mutation G248T (S83I) and Concurrent gyrA Mutations.

Journal of Infectious Diseases, 2019
BACKGROUND The basis of fluoroquinolone treatment failure for Mycoplasma genitalium is poorly understood. METHODS To identify mutations associated with failure we sequenced key regions of the M.
G. Murray, Kaveesha Bodiyabadu, J. Danielewski, S. Garland, D. Machalek, C. Fairley, J. Jensen, D. Williamson, L. Tan, E. Mokany, Duygu Durukan, C. Bradshaw   +11 more
semanticscholar   +1 more source

Carrier-free combination dry powder inhaler formulation of ethionamide and moxifloxacin for treating drug-resistant tuberculosis

Drug Development and Industrial Pharmacy, 2019
This study aimed to develop a combination dry powder formulation of ethionamide and moxifloxacin HCl as this combination is synergistic against drug-resistant Mycobacterium tuberculosis (Mtb). L-leucine (20% w/w) was added in the formulations to maximize
Mohammad A. M. Momin, Shubhra Sinha, I. Tucker, Shyamal C. Das   +3 more
semanticscholar   +1 more source

Antibiotic Resistance, Biofilm Formation, and Intracellular Survival As Possible Determinants of Persistent or Recurrent Infections by Staphylococcus aureus in a Vietnamese Tertiary Hospital: Focus on Bacterial Response to Moxifloxacin

Microbial Drug Resistance, 2019
Resistance is notoriously high in Asia but may not entirely explain therapeutic failures. Specific modes of bacterial life, such as biofilm or intracellular survival, may also contribute to the persistent and/or recurrent character of infections.
T. K. Nguyen, M. Argudín, A. Deplano, Phạm Hồng Nhung, H. A. Nguyen, P. Tulkens, M. Dodémont, F. Van Bambeke   +7 more
semanticscholar   +1 more source

Moxifloxacin-induced QT interval prolongation and torsades de pointes: a narrative review

Expert Opinion on Drug Safety, 2018
Introduction: Moxifloxacin is widely used for the treatment of a number of infectious diseases because of its favorable pharmacological profile and high clinical success rate.
Fahadullah Khan, M. Ismail, Q. Khan, Zahid Ali   +3 more
semanticscholar   +1 more source

Moxifloxacin

Reactions Weekly, 2010
  +6 more sources

Moxifloxacin

Tuberculosis, 2008
  +5 more sources

Moxifloxacin

Reactions Weekly, 2023
  +4 more sources

Moxifloxacin

Reactions Weekly, 2013
  +4 more sources

Moxifloxacin

Reactions Weekly, 2018
  +4 more sources

Green Synthesis of Silver Oxide Nanostructures and Investigation of Their Synergistic Effect with Moxifloxacin Against Selected Microorganisms

Journal of Inorganic and Organometallic Polymers and Materials, 2020
S. Haq, K. A. Yasin, W. Rehman, M. Waseem, M. N. Ahmed, M. Shahzad, N. Shahzad, A. Shah, M. Rehman, B. Khan   +9 more
semanticscholar   +1 more source